NCT01647256终止1 期
Comparison of Nikkomycin Z Bioavailability After Single Dose Administration Under Fed (High Fat Meal) Compared to Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Rate and extent of Nikkomycin Z absorption under fed and fasting conditions
研究概览
简要总结
The primary purpose of this study is to evaluate if eating a high fat meal versus not eating any food affects how the study drug (Nikkomycin Z) is absorbed into the body. The second purpose is to gain further information about the safety of Nikkomycin Z in healthy adults.
详细描述
To compare the single-dose bioavailability of Nikkomycin Z 500 mg (two 250 mg capsules) under fed and fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be at least 18 years of age and not over 40 years of age
- •Be male, or female (non childbearing potential or using adequate contraception)
- •Have a body mass index between 18 and 29 kg/m2
- •Able to understand the study and give written informed consent
- •Be determined healthy based on a medical and laboratory evaluation
排除标准
- •Patients under the age of 18 years or over 40 years of age
- •Current smoker or history of smoking within 3 months of participation
- •Inability to comprehend study and provide written informed consent
- •Inability to comply with the study requirements
- •History of or current evidence of major organ disease
- •Renal disease - serum creatinine > 1.5 mg/dL, significant hematuria or proteinuria, known structural abnormality or chronic kidney disease
- •Hepatic disease - active viral hepatitis, history of hepatitis B or hepatitis C, bilirubin > 2.0, ALT or AST above normal upper limit for laboratory, alcoholic liver disease, other chronic liver disease
- •CNS disease or cognitive dysfunction - any past history of epilepsy, CNS infections, stroke, CNS bleed, severe headaches, major psychiatric illness, or current mental status changes
- •Lung disease - history of severe asthma, COPD, pulmonary tuberculosis, or other major lung disease
- •Cardiac disease - history or current evidence of ischemic coronary artery disease, myocardial infarction, heart failure, or significant arrhythmia
- •Gastrointestinal disease - presence of inflammatory bowel disease, difficulty swallowing, or any gastrointestinal probably that would limit taking oral medications or that may compromise absorption of oral medications
- •Cancer - History of hematologic malignancy or solid tumor excluding basal cell carcinoma limited to the skin within the past 5 years
- •History of autoimmune or inflammatory disease such as rheumatoid arthritis and lupus
- •Immunocompromised state - solid organ transplant, cancer chemotherapy, stem cell transplant with graft versus host disease, immunosuppressive therapy, or HIV infection
- •Recent weight loss of greater than 10%
- •Any other history or evidence of disease that in the opinion of the physician would increase the risk for the subject for clinical trial participation
- •Regular use of prescription medications, over-the-counter medications, or dietary/herbal supplements within 14 days of day
- •Occasional use of acetaminophen or over-the-counter NSAID within the 14 day window may be allowed at the P.I. discretion
- •Subjects who received another investigational drug within 30 days of enrollment
研究组 & 干预措施
Nikkomycin Z fed - fasting
Experimental
Period 1:
- Day 1: Nikkomycin Z 500 mg with high fat breakfast
Period 2:
- Day 1: Nikkomycin Z 500 mg under fasted conditions
干预措施: Nikkomycin Z (Drug)
Nikkomycin Z fasting - fed
Experimental
Period 1:
- Day 1: Nikkomycin Z 500 mg under fasted conditions
Period 2:
- Day 1: Nikkomycin Z 500 mg with high fat breakfast
干预措施: Nikkomycin Z (Drug)
结局指标
主要结局
Rate and extent of Nikkomycin Z absorption under fed and fasting conditions
时间窗: 24 hours
次要结局
- Extent of Nikkomycin Z urinary excretion(24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Food Effect Study of 60mg ER TorsemideFood-drug InteractionNCT03215875Sarfez Pharmaceuticals, Inc.28
已完成
1 期
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal WomenHealthyNCT00465075Wyeth is now a wholly owned subsidiary of Pfizer24
进行中（未招募）
不适用
To determine oral bioavailability of the oral liquid formulation and potential food effects.EUCTR2011-001893-24-DEBayer HealthCare AG30
已完成
1 期
Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male SubjectsHealthyNCT03302078Boehringer Ingelheim12
已完成
1 期
Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy AdultsHealthy VolunteerNCT01634178Amgen46